Brendan Borrell | Aug 1, 2007 | 10+ min read
Selling Systems Biology Can this still-unproven (and much-hyped) field revolutionize drug discovery? By Brendan Borrell ARTICLE EXTRAS 1,2 suggested that the drug works primarily in patients with mutations in the ErbB1 epidermal growth factor receptor. The inner workings of the ErbB receptor family, with its sprawling pathways and multiple phosphatases, had long been a headache for drug makers. That complexity showed itself in this instance, too - sometimes the drug wa